A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Active, not recruiting · Phase 1 · NCT04419532
Conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $464,148
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS-1055a (drug)
- Dates
- Started 2020-10-09; completion 2027-07-01
- Results posted
- Not yet
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
From ClinicalTrials.gov, last updated 2026-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $464,148 in research payments for this study in 2025 (102 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Cincinnati $464,148
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.